RT Journal Article
T1 Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines
A1 Cáceres Ramos, Sara Cristina
A1 Alonso-Diez, Angela
A1 Crespo, Belén
A1 Peña Fernández, Laura Luisa
A1 Illera del Portal, Josefina María
A1 Silván Granado, Gema
A1 Andrés Gamazo, Paloma Jimena de
A1 Illera Del Portal, Juan Carlos
AB Xenografts can grow in immunosuppressed hosts, such as SCID mice, and tumor material can be injected into hosts either ectopically or orthotopically. Choosing the correct model to use is a crucial step in animal research. The aim of this study was to report the differences between ectopic and orthotopic xenografts in tumor progression, metastasis capacity, histological features, and steroid hormone profiles in xenografts from the cIMC (canine inflammatory mammary cancer) cell line IPC-366 and hIBC (human inflammatory breast cancer) cell line SUM149. To achieve this purpose, 40 female mice 6–8 weeks old were inoculated with IPC-366 and SUM149 cells subcutaneously (ectopic models) or into mammary fat pad (orthotopic models). Mice were monitored for tumor progression and appearance of metastases, and generated tumors were analyzed in terms of histological examination and steroid hormone production. The results revealed differences in tumor appearance and percentage of metastasis between ectopic and orthotopic models, which were higher in the ectopic xenografts from both cell lines. However, both models had similar characteristics of tumor progression, histological features, and steroid hormone secretion profiles. We show that the ectopic model can be validated as a good and useful model of tumor development in addition to, not contrary to, the orthotopic model in breast cancer research.
PB MDPI
YR 2021
FD 2021-09-13
LK https://hdl.handle.net/20.500.14352/95236
UL https://hdl.handle.net/20.500.14352/95236
LA eng
NO Caceres S, Alonso-Diez A, Crespo B, Peña L, Illera MJ, Silvan G, de Andres PJ, Illera JC. Tumor Growth Progression in Ectopic and Orthotopic Xenografts from Inflammatory Breast Cancer Cell Lines. Vet Sci. 2021 Sep 13;8(9):194. doi: 10.3390/vetsci8090194. PMID: 34564588; PMCID: PMC8470891.
DS Docta Complutense
RD 9 abr 2025